Moderna’s stock soars then dips after questions arise around the limited data shared about its COVID-19 vaccine
May 20, 2020 at 14:49 PM EDT
Investors in Moderna Inc., the preclinical biotechnology company developing one of the front-running COVID-19 vaccines in the U.S., may face a volatile ride through the clinical trial process.
